MORRISVILLE, N.C. (Aug. 18, 2008) - AVOS Life Sciences contends that Tysabri will exceed $1 billion in sales by 2014 as previously forecasted in the AVOS Therapeutic Market Outlook (TMO) Multiple Sclerosis Report released on July 1, 2008. In addition, the market dynamics featured in the report remain the same despite the recent cases of progressive multifocal leukoencephalopathy (PML) associated with Tysabri.
On July 31, 2008, Biogen Idec and Elan filed a current report with the Securities and Exchange Commission which was the first public disclosure of the two cases of PML in patients treated with Tysabri monotherapy. The cases were the first report of Tysabri patients suffering from PML since Tysabri was reintroduced to the market in 2006. The speed with which the cases were identified and treated is a testament to the success of the risk-management plans for Tysabri in place in Europe and the U.S.
“The recent cases of PML will not significantly affect the uptake prospects for Tysabri in our model over the course of the entire forecast period,” said Jim Wahl, principle analyst and author of the TMO Multiple Sclerosis report. “We stand by our projection that Tysabri will achieve blockbuster status by 2014.” Based upon information gathered from the AVOS Physician Panel, AVOS determined that neurologists were hopeful for Tysabri but remained apprehensive in prescribing the drug to a wider patient population until more long-term safety data becomes available. In addition to the investigation of input received from the AVOS Physician Panel, the AVOS TMO Multiple Sclerosis Report also probes five major developments affecting the market over the period from 2005-2014:
• Cautious optimism marks Tysabri’s return
• Oral therapies will alter the multiple sclerosis treatment paradigm
• Changes in physician attitudes and prescribing habits
• Market shifts will slow despite new treatment options
• Moderate market growth
AVOS’ analytical tools are structured to assist with real-time decision-making in a dynamic environment.
For more information:http://www.avoslifesciences.com/
Pharmiweb.com from Pharmiweb Solutions - CLICK HERE FOR FULL STORY
